On January 28, 2026, Shandong Shengdi Pharmaceutical Co., Ltd., a subsidiary of Hengrui Pharmaceutical, received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company's independently developed Class 1 innovative oral small molecule GLP-1 receptor agonist HRS-7535 tablets to conduct clinical trials for the indication of hypertension combined with overweight or obesity. Glucagon like peptide-1 receptor (GLP-1 R) agonists are a novel class of hypoglycemic and weight loss drugs.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
We provide GLP-1 Injections, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
In recent years, studies have found that GLP-1 R agonists can activate GLP-1 receptors, promote urinary sodium excretion, improve endothelial function, inhibit sympathetic nervous activity, regulate the renin angiotensin aldosterone system (RAAS), and thus exert antihypertensive effects. HRS-7535 tablet is a new oral small molecule GLP-1R agonist, which can not only promote insulin secretion of the pancreas and reduce glucagon secretion and inhibit gastric emptying by activating human GLP-1R, but also can be used to treat type 2 diabetes and obesity by influencing the central nervous system to enhance satiety and suppress appetite, and directly reduce energy intake. Currently, there are no oral small molecule GLP-1R agonists on the market worldwide.
Novartis' world's first small interfering RNA cholesterol lowering drug (Ingersoll Rand Sodium Injection) has been approved for a new indication
On January 28, 2026, Novartis announced that its innovative cholesterol lowering drug, Leclerc 8 (Ingersoll Rand Sodium Injection), has been approved by the China National Medical Products Administration as an adjuvant therapy for diet. It is used as a monotherapy for adult patients with primary hypercholesterolemia (non familial) or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C). This means that Ingersoll Rand Sodium Injection further covers more patients with dyslipidemia in need, based on the previously approved indications for combination therapy with statins or other lipid-lowering therapies.
As the world's first and currently only approved small interfering RNA cholesterol lowering drug targeting PCSK9, the administration method of "two injections per year" of Ingersoll Rand Sodium Injection is expected to improve treatment compliance and the long-term compliance rate of LDL-C, helping to achieve long-term standardized management of blood lipids.
As an innovative drug for reducing LDL-C, Ingersoll Rand can block the synthesis of the precursor protein convertase PCSK9 protein, which contributes to the elevation of LDL-C, from the source, thereby stabilizing the long-term reduction of LDL-C levels. According to the V-MONO China study conducted by Chuanqi Clinical, compared with placebo, in patients with low/moderate risk of ASCVD who did not receive lipid-lowering treatment, the use of Ingersoll Rand monotherapy achieved clinically and statistically significant LDL-C reduction efficacy compared to placebo.
Lekewei was first approved in China in August 2023 as a dietary adjuvant therapy for the treatment of adult patients with primary hypercholesterolemia (heterozygous familial and non familial) or mixed dyslipidemia. It includes the use of statins alone or in combination with other lipid-lowering therapies in patients who cannot achieve the LDL-C (low-density lipoprotein cholesterol) target despite receiving the maximum tolerated dose of statins, as well as in patients who are intolerant or contraindicated to statins. The aforementioned indications have been included in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue (2025)" on December 7, 2025. The single drug indications approved this time are not yet within the scope of medical insurance payment.
Huadong Pharmaceutical and Shian Biotechnology collaborate to innovate siRNA therapy and enter preclinical research stage
On January 29, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Huadong Pharmaceutical"), a wholly-owned subsidiary of Huadong Pharmaceutical Co., Ltd. (SZ. 000963), and Suzhou Shian Biotechnology Co., Ltd. (hereinafter referred to as "Shian Biotechnology") jointly announced that their strategic cooperation project, the siRNA innovative therapy for innovative weight loss mechanism, has successfully completed the confirmation of preclinical candidate compounds (PCC) and officially entered the preclinical research stage.
Huadong Pharmaceutical and Shian Biotechnology rely on the research and development advantages of both parties to focus on the unmet clinical needs of metabolic diseases such as obesity and non-alcoholic fatty liver disease (MASH), and accelerate the development of a new generation of metabolic disease treatment plans. This progress is an important milestone for both parties since reaching a cooperation agreement in early 2025.
Both parties will quickly advance the project into the preclinical research stage, and are expected to develop a new generation of small nucleic acid therapies in the field of weight loss; Shian Biotechnology has the right to receive project down payments, milestone payments, and a high proportion of overseas license sharing.
The characteristic of "one-time administration and long-term effectiveness" of siRNA perfectly meets the clinical needs of long-term management of metabolic diseases. Shian Biotech, relying on its independently developed AI based siRNA sequence design platform, eSAFE chemical modification branch, and STORK-L GalINAc coupling delivery technology and other core advantages in siRNA drug development, has worked closely with the R&D team of East China Medicine to successfully develop highly specific siRNA molecules for weight loss treatment.
Preliminary experimental data shows that it has significant therapeutic effects in reducing body weight and improving glucose and lipid metabolism, with good daily safety and the potential to become a "best in class" drug. In the future, Huadong Pharmaceutical will leverage its development capabilities, clinical resources, and commercialization experience in the field of metabolic diseases to lead clinical trial design, registration and application, and rapidly expand its global market. Both parties will continue to accelerate the clinical validation and industrialization process of this innovative therapy through complementary advantages.
